Nuclear apoptotic volume decrease in individual cells: Confocal microscopy imaging and kinetic modeling

Irina V. Khalo, Anastasiya I. Konokhova, Darya Y. Orlova, Konstantin V. Trusov, Maxim A. Yurkin, Valeri P. Maltsev, Andrei V. Chernyshhev

A R T I C L E   I N F O

Article history:
Received 18 October 2016
Revised 13 May 2018
Accepted 28 May 2018
Available online 30 May 2018

Keywords:
Apoptosis
Nuclear volume decrease
Chromatin condensation
Apoptotic ring
3D time lapse confocal microscopy
Live cell analysis
Kinetics
Mathematical modeling

A B S T R A C T

The dynamics of nuclear morphology changes during apoptosis remains poorly investigated and understood. Using 3D time-lapse confocal microscopy we performed a study of early-stage apoptotic nuclear morphological changes induced by etoposide in single living HepG2 cells. These observations provide a definitive evidence that nuclear apoptotic volume decrease (AVD) is occurring simultaneously with peripheral chromatin condensation (so called “apoptotic ring”). In order to describe quantitatively the dynamics of nuclear morphological changes in the early stage of apoptosis we suggest a general molecular kinetic model, which fits well the obtained experimental data in our study. Results of this work may clarify molecular mechanisms of nuclear morphology changes during apoptosis.

© 2018 Elsevier Ltd. All rights reserved.

1. Introduction

Apoptosis is an evolutionarily conserved type of programmed cell death initially recognized due to characteristically altered cell morphology (Kerr et al., 1972; Wyllie et al., 1980) and later associated with a variety of biochemical marks (Saraste and Pulkki, 2000; Williams et al., 1974). Successful initiation and execution of tightly regulated apoptotic program depends on activation of genetically controlled pathways mediated by a number of molecular participants from different cellular compartments and is reflected by yielding characteristic morphological and biochemical alterations that are mainly evident in the nucleus (Martelli et al., 2001; Robertson et al., 2000). The dynamics of nuclear morphology changes during apoptosis and mechanisms of apoptotic volume decrease (AVD) remain poorly investigated and understood. Even today, despite a large array of available biochemical as-

* Corresponding author at: Institute of Chemical Kinetics and Combustion, Institutskaya 3, Novosibirsk 630090, Russia.
E-mail address: chern@kinetics.nsc.ru (A.V. Chernyshhev).

https://doi.org/10.1016/j.jtbi.2018.05.034
0022-5193/© 2018 Elsevier Ltd. All rights reserved.
be involved in the “decision-making” commitment to cell killing (Samejima and Earnshaw, 2005). There is still no general mechanism proposed to describe nuclear shrinkage despite its seemingly obvious connection with chromatin condensation. The latter in its turn is considered a passive process resulting from the loss of chromatin and DNA structural integrity (Hendzel et al., 1998) and from changes in histone-DNA interactions (Allera et al., 1997). However remarkably little is known about the factors causing these structural changes. There are at least two redundant pathways leading to chromatin condensation and degradation (Susin et al., 2000).

The first caspase-independent pathway induces stage 1 of nuclear apoptosis and involves apoptosis-inducing factor AIF (Hangen et al., 2010; Loo et al., 2002; Maté et al., 2002; Sevrioukova, 2011; Susin et al., 1999), – the mammalian mitochondrial protein identified as a 57 kDa flavoprotein. The following supposed mechanism (Joza et al., 2009; Loo et al., 2002; Oberhammer et al., 1993; Susin et al., 1999) can be initiated either by a physical stimulus (e.g., noise exposure (Han et al., 2006) or UV-treatment (Pantic et al., 2012)) or a chemical agent (e.g., etoposide (Candé et al., 2002)). In healthy cells, AIF is located in the mitochondrial intermembrane space. During a certain time after the apoptosis initiation mitochondria still retain their integrity while swelling (this stage may be considered as a “lag phase”) until the mitochondrial outer membrane becomes ruptured (Han et al., 2006; Sesso et al., 2012; Sun et al., 2007), which leads to AIF exiting into the cytosol. Such mechanism explains the experimentally observed (Bhola et al., 2009) stepwise dynamics (i.e. with the delay time after the stimulation) of the initial stage of the apoptosis. It is also reflected in the corresponding stepwise kinetics of AIF appearance in cytosol near the nucleus. From cytosol AIF translocates into the nucleus and promotes chromatin condensation supposedly through direct binding with the DNA (Artus et al., 2010; Hangen et al., 2015; Maté et al., 2002; Sevrioukova, 2011; Susin et al., 1999; Ye et al., 2002) that occurs prior to the large-scale DNA degradation. The detailed molecular mechanism whereby AIF mediates apoptotic functions in a caspase-independent way remains unclear. AIF, however, is not the only supposed apoptotic effector, which releases from the ruptured mitochondria. Another apoptotic mitochondrial factor is 30 kDa protein endonuclease G (Li et al., 2001; Loo et al., 2002). Although originally identified as a protein involved in mitochondrial DNA replication, endonuclease G was later shown to be released (together with AIF) from mitochondria during apoptosis and to translocate to the cell nucleus, where it is involved in nuclear DNA breakdown (Patterson et al., 1997). The role of endonuclease G in apoptosis is far from being completely understood. Endonuclease-G–induced DNA degradation was shown to be independent of caspase activation, as is also the case for AIF. However, AIF is not a self-nuclease while endonuclease G is. Probably, endonuclease G alone is not sufficient, but requires other nucleases or cofactors. It is possible that both proteins (AIF and endonuclease G) do not act in isolation but require each other for full activity (Han et al., 2006).

The second pathway involving caspasess is required for late-apoptosis chromatin condensation and DNA cleavage. However, these pathways are likely to occur in parallel or even activate each other, and importance or order of activation of involved molecules probably depend on cell type and apoptotic stimulus (Candé et al., 2004). These open questions and remaining issues raise a clear need for single-cell analysis methods allowing rigorous quantitative characterization of nuclear-apoptotic-dynamics mechanism and considering individual cellular response. Nuclear apoptosis analysis is still predominantly tackled using population-based assays, using gene knockouts or treating inhibitors (Susin et al., 2000; Tone et al., 2007; Widlak et al., 2002), which provide at their best a relative quantification of nuclei which exhibit a set of particular hallmarks or relative changes in signal intensities.

Such approaches do not provide sufficient temporal and spatial resolution necessary for quantification of nuclear shape and chromatin structure changes on single-cell level. Thus, there is a vital need for methodology for detailed quantification of single-nucleus apoptotic dynamics, based on time-resolved assessment of volume and degree of chromatin condensation and nuclear shrinkage with an emphasis to the sequence and timing of these key stages of nuclear apoptotic program. That also implies a development of mathematical molecular-kinetic models, which are consistent with observable dynamics of nuclear morphological alterations and characterize them by a number of parameters. Such an enhanced approach would be significant from both basic research and clinical perspectives, e.g. in analysis of tumor cell sensitivity to a proapoptotic stimulus or drug.

We try to satisfy this methodological need by presenting an integrated method for the detailed quantitative analysis of the dynamics of early apoptotic nuclear morphological changes. Using time-lapse 3D confocal microscopy of living individual cells in apoptosis we developed a molecular kinetic model of peripheral chromatin condensation leading to the nuclear volume decrease on the early apoptotic stage.

2. Material and methods

2.1. Cell culture, transfection and apoptosis induction

HepG2 cell line stably expressing H4–Dendra2 (obtained from Professor Ivan Raška, Institute of Cellular Biology and Pathology, First Faculty of Medicine, Charles University, Prague, Czech Republic) were cultivated on microscopic 50-mm glass bottom dishes (MatTek, Corporation, Ashland, MA, USA; #PS0G-0-30-F) in Dulbecco’s modified Eagle’s Medium (PAN, Germany) supplemented with 10% fetal calf serum (PAN), 100 IU/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere containing 5% CO₂, at 37 °C.

To induce apoptosis cell were treated with etoposide (50 μM)–15 μl per 4 ml of media – right before the real-time microscopic measurements.

2.2. 3D time-lapse live-cell microscopy imaging

Time-lapse live-cell microscopy imaging was performed using Leica TSC SPS X microscope (Leica, Wetzlar, Germany), equipped with a white-light laser (WLL, 40 mW; Leica, Mannheim, Germany; 470–670 nm in 1 nm increments); 63×/1.4NA oil HCX PL APO lambda blue Objective (Leica) and a 5% CO₂, 37 °C humidified incubation chamber. For scanning WLL was set to 10% of maximal intensity at λ = 490 nm. 3D scanning of cells (pinhole diameter, 1 Airy; lateral resolution, 0.22 μm; axial resolution, 0.55 μm) and image acquisition were performed in a z-stack time lapse scanning mode using Leica LAS AF software (version 2.1.2). Stacks of 195 z-slices (1024 × 1024 pixels with pixel sizes 102.3 nm × 102.3 nm) were collected at 125.9 nm z-spacing and a rate of 2.6 s/slice during 9 h from the moment of cell’s treatment with the inducer of apoptosis. Each nucleus occupied less than 140 stacks, therefore it took less than 6 min to obtain every single 3D image of the nucleus.

2.3. Image processing and quantitative image analysis of nuclear apoptotic volume decrease and chromatin condensation

The image processing workflow is demonstrated in Fig. 2 for two nuclei demonstrating no apoptotic morphological features and apoptotic peripheral chromatin condensation, respectively. At the first stage (steps 1–3, Fig. 2A–D) confocal image data analysis is carried out using the freely available ImageJ2 software
(http://imagej.net/ImageJ2). The ImageJ macros (i) provides tracking of single cell nuclei by selection of corresponding ROI at each image sequence (time series), (ii) converts images to gray scale by splitting channels (the green one is selected due to detected fluorescent signal), (iii) corrects for uneven image noise using 3D median filtration with respect to spatial resolution and scan properties, (iv) creates a binary "chromatin" mask by segmentation of an area occupied by chromatin inside a nucleus using a predefined threshold intensity value and "opening" operator for additional morphological noise removal, (v) converts segmented chromatin binary mask to a finite sets of points (xyz coordinates) defining chromatin area as an input to the alpha-shape algorithm (LaFarge et al., 2014) to reconstruct the nuclear shape and estimate total nuclear volume, (vi) normalizes image intensity to correct fluorophore photobleaching, typical for time-lapse confocal observations (Pawley, 2010), assuming that cumulative intensity inside the chromatin mask, as well as total chromatin amount inside the nucleus, retains constant value during the whole observation. (vii) Condensed chromatin is detected on image stacks with normalized intensity by chromatin fluorescence intensity exceeding threshold value defined by maximum fluorescence intensity during initial observations when chromatin is assumed to be predominantly in uncondensed state.

Nuclear volume is nearly identical to the overall volume occupied by chromatin when it is uniformly distributed within the nucleus at the early stages of observations. However this is no longer true when early peripheral chromatin condensation begins. To take into account this volume underestimation and accurately measure the observable nuclear volume dynamics we perform reconstruction of the shape of whole nucleus defining it by surface confining the outer boundary of chromatin area. 3D reconstruction of this nuclear surface and nuclear volume estimation is performed by 3d alpha shape algorithm implemented in R package ‘alphashape3d’ (LaFarge et al., 2014) (Fig. 2).

3. Theory and calculation

3.1. Kinetic model of early apoptotic peripheral chromatin condensation and nuclear volume decrease

Kinetic model of peripheral chromatin condensation in the shape of a nuclear shell (so called "apoptotic ring") proposed here is based on a general mathematical description of the translocation of a specific apoptotic "effector" from the cytoplasm into the nucleus. We do not specify the name of the effector (e.g. AIF) since the detailed molecular mechanism of the chromatin condensation is unknown. However, it is known in the literature that AIF is absent before the condensation and is present during the condensation (Artus et al., 2010; Han et al., 2006; Ho et al., 2006; Scovassi et al., 2009; Ye et al., 2002), therefore the beginning of AIF translocation into the nucleus occurs simultaneously with the beginning of chromatin condensation. Moreover, the concentration of AIF is significantly higher in the area of the condensed chromatin (Artus et al., 2010; Ye et al., 2002) that indicates AIF is bound within the condensed chromatin with a high affinity constant. Therefore, AIF can be a candidate to the role of the apoptotic effector.

In order to mathematically describe the formation dynamics of the intranuclear peripheral shell of the condensed chromatin, we assume the following constrains of the proposed model: (1) the condensed chromatin is located only inside the apoptotic shell, whereas the uncondensed chromatin is located only outside the apoptotic shell in the nucleus (i.e. only the chromatin in the "apoptotic ring" is called "condensed chromatin" in the model); and (2) the concentration of the effector is equal to zero on the inner surface of the shell during the process (to avoid condensation in the center of the nucleus). Then the chromatin condensation occurs only on the inner surface of the shell, and thus the rate of the increase of the condensed chromatin amount (it is proportional to the shell volume) is proportional to the total flux of the effector on the inner surface of the shell (e.g., it is reported in the literature that irreversible binding of chromatin with AIF causes the chromatin condensation (Artus et al., 2010; Sevrioukova, 2011; Vahsen et al., 2006; Ye et al., 2002)).

In addition, we assume that the translocation dynamics of the external apoptotic effector through the nucleus is limited by its intranuclear diffusion through the apoptotic shell. That means the rate of the translocation of the effector through the apoptotic shell is much lower than both (1) the rate of the transport of the effector through the nuclear membrane (that is reasonable due to known fast transport rate of not-large proteins ~60 kDa through the nuclear membrane (Ma et al., 2012; Stewart, 2007; Yang et al., 2004), and AIF and endonuclease G are proteins of such molar mass) and (2) the rate of the chromatin condensation on the inner surface of the apoptotic shell (otherwise, the chromatin would be condensed everywhere inside the nuclear, but not only on the periphery that contradicts with experimental observations). To satisfy such limiting condition the translocation rate of the effector inside the shell should be much slower than in water, – that is possible in the case of a fast reversible binding reaction of the effector with the condensed chromatin (leading to so called "delayed diffusion" of the effector).

It is known in the literature (Kihlmark et al., 2001; Solier and Pommier, 2009, 2014) and also observed in our experiments that the intranuclear peripheral apoptotic shell of the condensed chromatin formed at early apoptosis (our stage I) has rather small thickness in comparison with both the nucleus size and characteristic curvature radius of its surface. This circumstance allows us to apply one-dimensional diffusion equation to describe the translocation dynamics of the effector through the shell of the condensed chromatin.

Therefore, in order to describe stage I, we suggest the following nonstationary (due to stepwise apoptotic dynamics) diffusion equation accompanied by ligand-receptor type reversible binding reaction (inside the shell of the condensed chromatin):

\[
\begin{align*}
\frac{\partial}{\partial t} G_u &= D \frac{\partial^2}{\partial x^2} G_u - k_d (A - G_b) G_u + k_d G_b \\
\frac{\partial}{\partial t} G_b &= k_d (A - G_b) G_u - k_d G_b \\
\frac{\partial}{\partial x} A &= -k_d (A - G_b) G_u + k_d G_b
\end{align*}
\]

where \(x\) is the coordinate across the apoptotic shell, \(G_u = G_u(x, t)\) is the local concentration of the unbound apoptotic effector, \(D\) is the diffusion coefficient (assumed to be a constant, i.e. independent of time \(t\) and spatial coordinates inside the nucleus), \(G_b = G_b(x, t)\) is the local concentration of bound complexes of the effector with condensed chromatin, \(A\) is the local concentration of the condensed chromatin binding sites (assumed constant, i.e. independent on \(t\) and \(x\) inside the shell), \(k_d\) is the association rate constant, \(k_d\) is the dissociation rate constant. In Eq. (1) we take into account the experimental fact that the diffusion of condensed chromatin is negligible on the time scale of stage I (Fig. 1).

In Eq. (1) we implicitly assume that they are unaffected by the parallel process of decreasing nucleus volume. More specifically, the apoptotic shell deforms elastically keeping its density and, hence, \(A\) constant. Then the whole volume change is due to the inner region occupied by uncondensed chromatin and, hence, accompanied by additional change of the concentration of the latter. However, this concentration is anyway irrelevant as long as chromatin condensation is fast enough (limited to the interior of the apoptotic shell). Then Eq. (1) are valid with respect to the moving reference frame (local to the surface element). The outflow of water through the nuclear membrane (and, hence, through the apoptotic shell) in the reverse direction affects only \(G_u\), which we
Fig. 1. Model of nuclear apoptotic volume decrease and peripheral chromatin condensation during early stages of nuclear apoptosis. During the lag-phase ($T_0$) mitochondria swell until rupture leading to the apoptotic effector translocation from mitochondria into the cytoplasm. On stage I, upon intranuclear penetration the effector initiates chromatin condensation. During this time ($\Delta T$) chromatin gradually condenses against the nuclear periphery forming characteristic shell-like area (so called “apoptotic ring” on 2D pictures). Alterations in chromatin structure result in nuclear volume decrease. By the end of stage I ($T_{end}$) and beginning of stage II the nucleus volume achieves a final value ($V_{end}$).

Further assume to be negligibly small. We want to emphasize that this model is applicable to a nucleus of arbitrary shape as long as the above assumptions are satisfied. The differential equation for the total concentration of the effector $G = G_u + G_b$ is obtained from Eq. (1) as follows:

$$\frac{\partial}{\partial t} G = D \frac{\partial^2}{\partial x^2} G_u$$

To solve Eqs. (1) and (2) we used the following two assumptions. First, the duration of stage I is much longer than the time of reaching the equilibrium of the reversible binding reaction (between the effector and the chromatin); thus assumption is justified by the significantly delayed diffusion, and leads to

$$k_d(A - G_b)G_u - k_dG_b = 0$$

Second, the concentration of bound complexes is much less than the total concentration of binding (i.e. both bound and unbound) sites in the shell of condensed chromatin:

$$G_b \ll A$$

Assumption (4) is equivalent to the requirement that the concentration of unbound effector $G_u$ is much less than the equilibrium constant $K = k_d/k_a$ of the effector-chromatin binding:

$$G_u \ll K = k_d/k_a$$

In the case of AIF, assumption (5) is supported by known literature experimental data on typical intranuclear total (i.e. both bound and unbound) concentration of AIF ($<3 \mu g/mL$ or $<6 \cdot 10^{-8}$ M (Sun et al., 2017)) (during stage I of apoptosis), which is much less
than the reported equilibrium constant \( K = 9 \times 10^{-7} \text{M} \) (Gong et al., 2007) of reversible binding of AIF with chromatin.

The above two assumptions (3)-(4) lead to the following algebraic relation:

\[ G = (1 + k_A/k)G_u \]  

Then, Eq. (2) is converted into the form of effective diffusion equation, which we use as a master equation in our model:

\[ \frac{\partial}{\partial t} G = \frac{D}{1 + k_A/k} \frac{\partial^2}{\partial x^2} G_u = D_{\text{eff}} \frac{\partial^2}{\partial x^2} G \]  

Eq. (7) is a reasonable and commonly applicable approach (Orlova et al., 2011), which introduces the effective diffusion coefficient \( D_{\text{eff}} \) (replacing the intrinsic diffusion coefficient \( D \) of AIF as water) to describe the diffusion delayed (since \( D_{\text{eff}} < D \)) by the binding. In order to solve Eq. (7) we formulated proper boundary conditions presented below.

Let \( X(t) \) be the coordinate of the inner surface area of the intranuclear apoptotic shell (\( x = 0 \) at the outer surface of the shell), which is the boundary between two phases of the chromatin: condensed and uncondensed ones. The shell inner boundary is moving (i.e. \( X(t) \) is increasing) during the chromatin condensation, and the boundary moving rate \( (dX/dt) \) depends on the condensed chromatin formation rate \( (dN_c/dt) \) as follows:

\[ \frac{1}{\rho_c} \frac{dN_c}{dt} = \frac{dV_c}{dt} = \frac{d(SX)}{dt} = S \frac{dX}{dt} + X \frac{dS}{dt} \]  

where \( S \) is the outer surface area of the shell, \( \rho_c \) is the molar density (or concentration) of the condensed chromatin (assumed a constant). The second term \( (X \cdot dS/dt) \) in the right side of Eq. (8) can be neglected under the following condition, which we assumed in our model:

\[ dX \gg \frac{X}{S} \]  

In general, the change of the nuclear surface area (during nuclear shrinking) could be explained by the highly folded structure of the nuclear membrane (Dahl et al., 2004). Nevertheless, we believe that condition (9) is a reasonable approximation (which allows to get an analytical solution of master Eq. (7)) in our model, since we found in this work that the shell surface area \( S \) reduces slightly while the condensed chromatin volume \( V_c = SX \) increases significantly (Fig. 4). That is also supported by known in the literature (Versaevel et al., 2012) and observed in our experiments phenomenon that during chromatin condensation the nucleus rather changes its shape index (becomes more elongated) that allows major change of the volume at minor change of the surface area.

Apoptotic condensation of chromatin takes some amount of the effector, which becomes irreversibly bound with the condensed chromatin (e.g. it is reported in the literature (Valsen et al., 2006) that chromatin is condensed with the ratio of one AIF molecule to 10 nucleotide), therefore, one can write:

\[ N_c = \xi N_c \]  

where \( \xi \) (assumed to be a constant) is the amount of irreversibly bound effector \( N_c \) per unit amount of condensed chromatin \( N_c \). Since there is no effector in the phase of uncondensed chromatin, the amount of the effector irreversibly bound per unit time (i.e. the rate of irreversible binding of the effector with uncondensed chromatin) on the inner surface of the shell should be equal to the diffusion flux of the effector at this boundary:

\[ \frac{dN_c}{dt} \bigg|_{x=X(t)} = -SD_{\text{eff}} \frac{\partial G}{\partial x} \bigg|_{x=X(t)} \]  

Combining Eqs. (8)-(11) we get:

\[ \frac{dX}{dt} = -\frac{D_{\text{eff}}}{\xi \rho_c} \frac{\partial G}{\partial x} \bigg|_{x=X(t)} \]  

Thus, we get the following moving boundary conditions for master differential Eq. (7):

\[ 0 \leq X(x, t), \quad t = 0 : \quad X(0) = 0, \quad G(x, 0) = 0 \]

\[ x = 0, \quad t > 0 : \quad G(0, t) = G_0 \]

\[ x = X(t), \quad t > 0 : \quad G(x, t) = 0 \]

\[ x = X(t), \quad t > 0 : \quad -\frac{dG}{dx} \bigg|_{x=X(t)} = \gamma \frac{dx}{dt} \]

where \( G_0 \) is the concentration of the effector in cytosol (i.e. on the outer surface of the shell) assumed to be constant (i.e. changed insignificantly) during stage I (in the case of AIF that was experimentally observed in the literature (Sun et al., 2017) and can be theoretically explained by the excess of the total amount of the effector in the cell over the total amount of effector-chromatin bound complexes formed in the nucleus), and \( \gamma \) is the coefficient derived from Eq. (12):

\[ \gamma = \frac{\xi \rho_c}{D_{\text{eff}}} \]  

Partial differential Eq. (7) with moving boundary conditions (13) is known as one-dimensional two-phases Stefan problem (Meirmanov, 1992; Rubinstein, 2000), which fortunately can be solved analytically (Javierre et al., 2006) using a special function, as follows:

\[ G(x, t) = G_0 \left( 1 - \frac{\text{erf}(x/\sqrt{4D_{\text{eff}}t})}{\text{erf}(\lambda)} \right) \]  

\[ X(t) = \lambda \sqrt{4D_{\text{eff}}t} \]  

where \( \text{erf}(y) \) is the (Gauss) error function:

\[ \text{erf}(y) = \frac{1}{\sqrt{\pi}} \int_{-y}^{y} e^{-z^2} dz \]  

It follows from Eq. (12) that constant parameter \( \lambda \) in Eq. (15) is determined by the equation:

\[ \frac{\sqrt{\pi \lambda}}{G_0} D_{\text{eff}} = \lambda \exp(\lambda^2) \text{erf}(\lambda) = 1 \]

which can be rewrote taking into account Eq. (14) as follows:

\[ \frac{G_0}{\sqrt{\pi \lambda} \rho_c} = \exp(\lambda^2) \text{erf}(\lambda) \]

Eq. (19) can be rewrote in a more convenient form (for practical applications) taking into account Eq. (10):

\[ \frac{G_c}{G_0} = \frac{1}{\sqrt{\pi \lambda} \exp(\lambda^2)} f(\lambda) \]

where \( G_c = \xi \rho_c \) is the concentration of irreversibly bound effector in the phase of condensed chromatin. Thus, Eq. (20) establishes the relation between the fraction \( (G_c/G_0) \) of irreversibly bound effector and the parameter \( \lambda \), which determines the condensed chromatin volume as follows from Eq. (16):

\[ V_c = SX = S \lambda \sqrt{4D_{\text{eff}}t} \]

It is known (Athirasala et al., 2017; Versaevel et al., 2012) that volume (and shape) of interphase nucleus is rather sensitive to the level of chromatin condensation. The condensation of chromatin is characterized by a reduction of volume due to a spatial organization into densely packed higher-order structures (Morales-Bermudez and Ellenberg, 2007). We assumed that the condensed chromatin volume is (approximately) linear proportional to the nuclear volume loss:

\[ V_c = \eta (V_0 - V) \]

where the coefficient \( \eta \) is a constant. Obviously, linear Eq. (22) should be applicable up to some (at least rather
small) extent of nuclear deformation. The dependence similar to linear Eq. (22) could be found in literature (Versaevel et al., 2012) for some cells. In our experiments with HepG2 linearity of Eq. (22) was verified in the range of the nuclear volume loss from zero up to 35% of the initial nuclear volume (Figs. 5 and 4).

Taking into account Eq. (22) and the duration $T_0$ of the lag phase (with the constant nuclear volume $V_0$) we get from Eq. (21) for the nuclear volume $V(t)$:

$$V(t) = \begin{cases} V_0 & \text{if } t < T_0 \\
V_0 - \sqrt{\frac{\beta}{T_0}} (t - T_0) & \text{if } T_0 \leq t \leq T_{\text{end}} \\
V_0 - \sqrt{\frac{\beta}{T_{\text{end}} - T_0}} (T_{\text{end}} - t) & \text{if } t > T_{\text{end}} \end{cases}$$

(23)

where

$$\beta = \frac{4D_{eff} S^2 \lambda^2}{\eta^2}$$

(24)

and $T_{\text{end}}$ is the time corresponding to the end of the condensation process, when all chromatin condensed and the nucleus volume changed in $\delta$ (“shrinking volume”) times and became $V_{\text{end}}$:

$$V_{\text{end}} = V_0 - \sqrt{\beta (T_{\text{end}} - T_0)} = V_0 \delta$$

(25)

Then the evolution of the condensed chromatin volume is expressed as

$$V_c(t) = \begin{cases} 0 & \text{if } t < T_0 \\
\sqrt{\frac{\beta}{T_0}} (t - T_0) & \text{if } T_0 \leq t \leq T_{\text{end}} \\
\sqrt{\frac{\beta}{T_{\text{end}} - T_0}} (T_{\text{end}} - t) & \text{if } t > T_{\text{end}} \end{cases}$$

(26)

Eqs. (23) and (26) describes the dynamics of stage I of chromatin condensation at the nuclear periphery and corresponding nuclear volume decrease ($T_0 < t < T_{\text{end}}$). The subsequent apoptotic nuclear morphological changes are not accompanied by further chromatin condensation and decrease in nuclear volume that achieves a final constant value $V = V_{\text{end}}$ (stage II, $t > T_{\text{end}}$) and include more advanced rearrangement of condensed chromatin inside the nucleus into separate clusters. With respect to parameters $V_0$, $V_{\text{end}}$, $T_{\text{end}}$, $T_0$ and $T_{\text{end}}$ the parameter $\beta$ can be expressed from Eq. (23) as

$$\beta = \frac{(V_0 - V_{\text{end}})^2}{\Delta T}$$

(27)

$$\Delta T = T_{\text{end}} - T_0$$

(28)

and, therefore, Eq. (23) can be rewritten into the following form, which is convenient for practical applications:

$$V(t) = \begin{cases} V_0 & \text{if } t < T_0 \\
V_0 - (V_0 - V_{\text{end}}) \sqrt{\frac{T_0 - t}{T_0}} & \text{if } T_0 \leq t \leq T_{\text{end}} \\
V_{\text{end}} & \text{if } t > T_{\text{end}} \end{cases}$$

(29)

Due to Eq. (22), the volume of the apoptotic shell can be fitted by Eq. (29), as well.

Using Eq. (24) one can evaluate the effective diffusion coefficient $D_{eff}$ of the effector from the obtained $\beta \eta^2$ (or final apoptotic shell volume $V_c$, or thickness $X_c$, or duration $\Delta T$ of stage I) and $S$, if $\lambda$ is known:

$$D_{eff} = \frac{\beta \eta^2}{4S^2} = \frac{V_c^2}{4S^2 \lambda^2 \Delta T} = \frac{X_c^2}{4S^2 \Delta T}$$

(30)

According to Eq. (20), required parameter $\lambda$ can be obtained from the measured fraction $G_c/G_0$ of irreversibly bound effector (e.g. in particular experiments by labeling the effector with a fluorophore). For example, if the fraction $G_c/G_0$ is equal to 1, the value of $\lambda$ is equal to 0.62. Interestingly, the function $f(\lambda)$ in Eq. (20) is changing significantly with $\lambda$: the variation of the fraction $G_c/G_0 = f(\lambda)$ in the wide range from $10^{-3}$ to $10^{3}$ corresponds to the variation of $\lambda$ in the relatively narrow range from 0.15 to 1.4 (Fig. 3).

Therefore, the parameter $\lambda$ can be evaluated with rather high precision even if the ratio $G_c/G_0$ is estimated approximately in the range of a few orders of magnitude.

### 3.2. Characterization of nuclear morphological changes in HepG2 cells treated with etoposide: fitting and statistical analysis

Quantitative assessment of nuclear surface, volume and condensed chromatin changes in HepG2 H4-Dendra2 cells undergoing etoposide-induced apoptosis was obtained using image processing algorithm shown in Fig. 2. Global optimization algorithm DiRect (Jones et al., 1993) implemented in LabView was used to fit the observable dynamics by the developed coupled model of early apoptotic chromatin condensation and nuclear volume decrease and retrieve the model parameters including uncertainties of estimates.

### 4. Results

Using time-lapse 3D confocal microscopy during 9h after etoposide treatment we observed the chromatin condensation forming the peripheral nuclear shell (so called “apoptotic ring”) at the early apoptosis stage on HepG2 cell line, expressing a fluorescent chromatin marker (histone H4-Dendra2). The observed nuclei reproduced all characteristic signs of early nuclear apoptosis that forced us to suggest the following stages for nuclear morphological changes starting from apoptosis induction time-point: relatively long initial lag-phase, where nucleus preserves its non-apoptotic appearance; fast stage I of peripheral chromatin condensation; and late stage II of the condensed chromatin exhibiting increasing fragmentation into separate beads. Both characteristic features of chromatin changes and transition times agree in part with previously performed in vitro dynamic studies (Tone et al., 2007). Schematically these stages are illustrated in Fig. 1 with basic cellular characteristics and typical 2D slices of corresponding 3D images obtained in this work.

In order to perform the quantitative analysis of observed dynamics of nuclear morphology changes of the cells we applied the developed kinetic model (Fig. 1, Material and Methods). It should be noted that the applicability of the model in processing of experimental kinetics of nuclear alterations depends on cellular characteristics, which can be retrieved from 3D images of cells. To satisfy this requirement we applied the original image-processing algorithm (Fig. 2, Material and Methods) to reconstruct a region occupied by condensed chromatin and the whole nuclear shape at each time point and to quantify dynamics of nuclear volume decrease and chromatin condensation during the whole observation. Finally, we fitted the experimentally measured dynamics of apoptotic volume decrease and peripheral chromatin condensation (the apoptotic shell formation) by Eq. (29) of the proposed model using global optimization (Fig. 4). As a result of this study we determined the following apoptotic characteristics for two analyzed cells: the initial $V_0$ and the final volumes of the nucleus $V_{\text{end}}$ and the condensed chromatin $V_c$, the lag-phase duration $T_0$, and the duration $\Delta T$ of stage I. These data allow one to evaluate the volume ratio $\delta$, the rate $\beta$ and the coefficient $\eta$ of the nuclear shrinkage.

In both cells observations, the nuclear volume loss was ~40%. The prolonged lag-phase of one of the observed cells prevented the detailed description of stage II of nuclear apoptosis (Fig. 4). However clearly visible patterns of condensed chromatin inherent to stage II in the last measured image series confirm that stage I of apoptotic shell formation was observed to the full extent to allow accurate characterization. Demonstrating similar degree of volume decrease and lag-phase duration the cells displayed a significantly different duration of stage I (but both values are within the reported temporal range (Tone et al., 2007)), thus demonstrating
cell-to-cell variability (mainly in supposed difference of their mitochondria life-times) in response to chemotherapeutic agent (etoposide).

Independent fitting of the nucleus volumes and the apoptotic shell volume in Fig. 4 by universal Eq. (29) supports one of main statements of the model that chromatin condensation occurs synchronously with the nucleus volume decrease: the lag-phase duration $T_0$ and the duration $\Delta T$ of stage I are equal (in frames of the error) for both volumes. Another important assumption on the approximate conservation of the surface area $S$ during early apoptosis is also supported by our measurements, as shown in Fig. 4. Normalized dependence of the nuclear volume on the condensed chromatin volume (values of $V_0$, $V_{END}$ and $V_{cond}$ are taken from Fig. 4) treated by linear fit in Fig. 5 justifies the important assumption of Eq. (22) used in our model.

5. Discussion

Kinetic model of peripheral chromatin condensation can be interpreted biologically through an apoptotic effector, responsible for initiation of chromatin structure remodeling. Dynamics of chromatin shell formation is limited by the diffusion of the effector through increasing shell of condensed chromatin at the inner face of the nuclear envelope. Particular nature of this effector and its mode of action has not been yet thoroughly studied and completely understood. As mentioned previously, AIF (or endonuclease G, or both) may initiate early chromatin condensation upon its nuclear translocation and change chromatin structure as a result of direct binding to DNA (Loo et al., 2002; Ye et al., 2002) or forming remodeling complexes in cooperation with other nuclear proteins (e.g. histone protein $\gamma$H2AX (Baritaud et al., 2010)). In order to finally elucidate this issue additional experimental evidence might be obtained by incorporating other fluorescent readouts. However,
the nature and intranuclear activity of hypothesized effector can also be evaluated indirectly from dynamic characteristics provided by the model, including lag-phase duration related to the time required for effector activation in the cytoplasm, and the rate and duration of stage I chromatin condensation related to the particular mechanism of effector’s action.

Whereas dynamics of chromatin condensation reflects biochemical aspects of apoptosis, we assume that nature of nuclear shrinkage is predominantly physicochemical. An immediate corollary of this model is direct interrelation between dynamics of nuclear shrinkage and chromatin condensation, which calls for simultaneous observation of dynamics of these processes.

Experimental observation of nuclear volume decrease simultaneous to chromatin condensation (Fig. 4) is consistent to our assumption of underlying mechanism. Thus, our approach does not only provide direct experimental evidence of the connection between these two inherent apoptotic features, but also supports it by quantitative evaluation. The apparent contradiction to previously reported shrinkage beginning during stage II (Tone et al., 2007) is likely related to abovementioned differences in the interpretation of term “shrinkage”. While we consider overall nuclear volume decrease supported by its direct measurement, the other study operates “nuclear shrinkage” as overall compaction of the chromatin related to its relative density.


